Today (2017 C.E. - 2025 C.E.)

This archive spans the years 2017 through 2025, a period marked by rapid advances in clean energy, medicine, technology, and social equity. It collects documented breakthroughs, policy wins, and scientific achievements from the present era. If you want evidence that progress is real and ongoing, this is where to look.

Pig embryo with human kidney, for article on pig-human chimera

Chinese researchers grow world’s first human organ inside a non-human animal

By / / Good News For Humankind

Human kidney tissue has been grown inside a pig embryo for the first time, with roughly half the cells in the developing kidney being human. Researchers in Guangzhou reprogrammed adult human cells, then injected them into pig embryos engineered to leave a “gap” where their own kidneys would form. The human cells moved in and self-organized into an early-stage kidney structure over 28 days of gestation. It’s not a transplantable organ, and real ethical questions remain about keeping human cells out of pig brains. But for the 100,000 Americans waiting for a kidney right now, this is a meaningful step toward a future where no one dies waiting.

Pills and syringe, for article on fentanyl vaccine human trials

Scientists preparing first human trials for vaccines that block the effects of deadly opioids

By / / Good News For Humankind

Fentanyl vaccines are heading into their first human trials, with Phase 1 testing set to begin in early 2024 at Columbia University. Developed by researchers at the University of Montana and University of Washington, the vaccines train the immune system to grab fentanyl molecules in the bloodstream, like a sponge, before they can reach the brain. That means no high, and no slowed breathing, which is what makes overdoses fatal. The team is especially focused on people in the first two years of recovery, when relapse risk is highest. If it works, this could become a powerful new tool in a crisis that has demanded every bit of compassion and ingenuity we can offer.

Model of a heart, for article on muvalaplin Lp(a) cholesterol

World-first drug lowers genetic form of “bad cholesterol” by up to 65%

By / / Good News For Humankind

Muvalaplin, a new pill from researchers at Monash University, lowered a dangerous genetic form of cholesterol by up to 65% in just two weeks during early trials. The drug targets lipoprotein(a), or Lp(a), a stickier cousin of LDL cholesterol that’s been called a “silent killer” because diet, exercise, and statins can’t touch it. Roughly one in five people worldwide carry elevated Lp(a), inherited risk they’ve long been told there’s nothing to do about. That muvalaplin works as a simple oral tablet, not an injection, could make it widely accessible if larger trials succeed. For global heart health, it’s a hopeful sign that even risks written into our DNA may not be the final word.

"Break free from fossil fuels" sign, for article on fossil fuel electricity

E.U.’s use of fossil fuels for electricity falls 17% to ‘record low’ in first half of 2023

By / / Good News For Humankind

Fossil fuels generated just 33% of the European Union’s electricity in the first half of 2023, the lowest share ever recorded. Coal had an especially striking moment: in May, it covered only 10% of EU power, and the Netherlands ran 17 straight days without burning any at all. Seventeen member states set new records for renewable generation, with Portugal and Denmark both crossing 75%. Solar kept climbing, and wind and solar together outproduced fossil fuels across the bloc in May for the first time. It’s a real glimpse of what a cleaner grid looks like — and a reminder that the next push is building enough renewables, storage, and grid capacity to power everything we’ll ask of electricity next.